Results 11 to 20 of about 50,364 (223)

Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab

Journal of International Medical Research, 2020
Nivolumab is an immune checkpoint inhibitor that is used to treat various advanced cancers, including metastatic non-small cell lung cancer (NSCLC). Nivolumab treatment has different side effects.
Zhihui Cai, Yuan Yao
doaj   +1 more source

Continuous drainage for the treatment of gastric cancer with pericardial metastasis and cardiac tamponade: A case report

Clinical Case Reports, 2023
Key Clinical Message Signet‐ring cell gastric carcinomas presenting as pericardial effusion early in diagnosis are rare and associated with high mortality and a poor prognosis.
Tadayuki Hirai, Wataru Omi, Yoichiro Nakagawa, Yusuke Shinjo, Yoshitaka Okabe, Chieko Kato, Takahiro Saeki, Satoru Sakagami   +7 more
doaj   +1 more source

Diagnosis and management of pericardial effusion

Journal of Mind and Medical Sciences, 2020
Pericardial effusion is a common pathology in clinical practice. The etiology of pericardial effusion is diverse, from infectious diseases, malignancies, autoimmune diseases, chronic renal failure, to drug-related or after an invasive cardiac ...
Maria Manea, Ovidiu Gabriel Bratu, Nicolae Bacalbasa, Camelia Cristina Diaconu   +3 more
doaj   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Pericardial Effusion

Cardiology Clinics, 2017
The normal pericardial sac contains up to 50 mL of fluid, which consists of a plasma ultrafiltrate. Anything greater constitutes a pathologic effusion. The curvilinear pressure-volume relationship of the pericardial sac dictates hemodynamic consequences of a pericardial effusion and is responsible for rapidly accumulating fluid that causes cardiac ...
Amir, Azarbal, Martin M, LeWinter
openaire   +3 more sources

Serum BNP levels are associated with malignant pericardial effusion

International Journal of Cardiology: Heart & Vasculature, 2019
Introduction: The development of malignant pericardial effusion indicates a poor prognosis and is the leading cause of cardiac tamponade. The objectives of the study were to examine the levels of BNP in traumatic, malignant and non-malignant pericardial ...
Shemy Carasso, Liza Grosman-Rimon, Ali Nassar, Fabio Kusniec, Diab Ghanim, Gabby Elbaz-Greener, Wadi Kinany, Doron Sudarsky, Evgeni Hazanov, Offer Amir   +9 more
doaj   +1 more source

Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?

Frontiers in Oncology, 2022
Pericardial effusion is a common finding in advanced-stage lung cancer. The presence of malignant cells or drainage of exudate effusion in the pericardial space may cause symptoms of dyspnea, pleuritic chest pain, and syncope.
Varsha Chiruvella, Asad Ullah, Islam Elhelf, Nikhil Patel, Nagla Abdel Karim   +4 more
doaj   +1 more source

Pericardial Effusion [PDF]

Circulation, 1971
Both a pericardial effusion and a failing myocardium can produce the roentgen appearance of a large, smoothly dilated heart which shows little evidence of pulsations. The correct diagnosis is often suggested by the appearance of the hilar vessels which are usually obscured by the cardiac shadow that is enlarged by a pericardial effusion, and not by the
openaire   +2 more sources

Diagnostic Utility of Cyfra 21-1 and Cea Assays in Pericardial Fluid for the Recognition of Neoplastic Pericarditis

The International Journal of Biological Markers, 2005
A positive cytology result in pericardial fluid is the gold standard for recognition of malignant pericardial effusion. Unfortunately, in 30–50% of patients with malignant pericardial effusion cytological examination of the pericardial fluid is negative.
M. Szturmowicz, W. Tomkowski, A. Fijalkowska, W. Kupis, A. Cieślik, U. Demkow, R. Langfort, A. Wiechecka, T. Orlowski, A. Torbicki   +9 more
doaj   +1 more source

Navigating the International System for Reporting Serous Fluid Cytopathology in pericardial effusion: A meta-analysis. [PDF]

Cancer Cytopathol
Abstract Background The International System for Reporting Serous Fluid Cytopathology (TIS) provides a standardized framework for classifying serous fluid cytology into five diagnostic categories: nondiagnostic, negative for malignancy, atypical, suspicious for malignancy, and malignant.
Arshia A, Kalfert D, Kholová I.
europepmc   +2 more sources